See accompanying notes to unaudited
condensed consolidated financial statements.
See accompanying notes to unaudited condensed consolidated
financial statements.
See accompanying notes to unaudited condensed consolidated
financial statements.
See accompanying notes to unaudited condensed consolidated
financial statements.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
JUNE 30, 2021
NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
The Company is a Delaware corporation, incorporated on July 17, 1987
and has been engaged in the intellectual property monetization business since 2008.
As used herein, the “Company” refers to Quest Patent Research
Corporation and its wholly and majority-owned and controlled operating subsidiaries unless the context indicates otherwise. All intellectual
property acquisition, development, licensing and enforcement activities are conducted by the Company’s wholly and majority-owned
and controlled operating subsidiaries.
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the US (GAAP) for interim financial information and
with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these interim financial statements do not include all
of the information and notes required by GAAP for complete financial statements. All adjustments (consisting of normal recurring items)
necessary to present fairly the Company’s consolidated financial position have been included. These interim financial statements
should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s annual
report on Form 10-K for the year ended December 31, 2020. Operating results for the interim periods presented herein are not necessarily
indicative of the results that may be expected for any other interim period or for the entire year. Reclassifications have been made to
conform with the current year presentation.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation and financial statement presentation
The consolidated financial statements are prepared in accordance with
U.S. generally accepted accounting principles (“US GAAP”) and present the consolidated financial statements of the Company
and its wholly owned and majority owned subsidiaries as of June 30, 2021.
The consolidated financial statements include the accounts and operations
of:
|
Quest Patent Research Corporation (“The Company”)
|
|
Quest Licensing Corporation (NY) (wholly owned)
|
|
Quest Licensing Corporation (DE) (wholly owned) (“QLC”)
|
|
Quest Packaging Solutions Corporation (90% owned)
|
|
Quest NetTech Corporation (65% owned) (“NetTech”)
|
|
Semcon IP, Inc. (wholly owned) (“Semcon”)
|
|
Mariner IC, Inc. (wholly owned) (“Mariner”)
|
|
IC Kinetics, Inc. (wholly owned) (“IC”)
|
|
CXT Systems, Inc. (wholly owned) (“CXT”)
|
|
Photonic Imaging Solutions Inc. (wholly owned) (“PIS”)
|
|
M-RED Inc. (wholly owned) (“M-Red”)
|
|
Audio Messaging Inc. (wholly owned) (“AMI”)
|
|
Peregrin Licensing LLC (wholly owned) (“PLL”)
|
|
Taasera Licensing LLC (wholly owned)
|
Significant intercompany transaction and balances have been eliminated
in consolidation.
Use of Estimates
In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and
revenue and expenses during the reporting period. Actual results could differ from those estimates.
Intangible Assets
Intangible assets consist of patents which are amortized using the
straight-line method over their estimated useful lives or statutory lives whichever is shorter and are reviewed for impairment upon any
triggering event that may give rise to the assets ultimate recoverability as prescribed under the guidance related to impairment of long-lived
assets. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line
basis with the associated patent.
Patents include the cost of patents or patent rights (hereinafter,
collectively “patents”) acquired from third-parties or acquired in connection with business combinations. Patent
acquisition costs are amortized utilizing the straight-line method over their remaining economic useful lives, ranging from one to ten
years. Certain patent application and prosecution costs incurred to secure additional patent claims that, based on management’s
estimates are deemed to be recoverable, are capitalized and amortized over the remaining estimated economic useful life of the related
patent portfolio.
Warrant liability
The Company reflects a warrant liability with respect to warrants for
which number of shares underlying the warrants is not fixed until the date of the initial exercise. The amount of the liability is determined
at the end of each fiscal period and the period to period change in the amount of warrant liability is reflected as a gain or loss in
warrant liability and is include under other income (expense).
Fair value of financial instruments
Fair value is defined as the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in
an orderly transaction between market participants on the measurement date. A fair value hierarchy is used which requires an entity to
maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. See Note 4 for information
about derivative liabilities.
The fair value hierarchy based on the three levels of inputs that may
be used to measure fair value are as follows:
|
Level 1 –
|
Quoted prices in active markets for identical assets or liabilities.
|
|
Level 2 –
|
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
|
Level 3 –
|
Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
|
The carrying value reflected in the consolidated balance sheets for
cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and short-term borrowings approximate fair value
due to the short-term nature of these items.
Income Tax
The Company incurred no foreign income tax expenses for the three and six
months ended June 30, 2021, and approximately $65,000 for both the three and six months ended June 30, 2020.
Inventor/Former Owner Royalties and Contingent Legal/Litigation
Finance Expenses
In connection with the investment in certain patents and patent rights,
certain of the Company’s operating subsidiaries may execute related agreements which grant to the inventors and/or former owners
of the respective patents or patent rights, the right to receive a percentage of future net revenues (as defined in the respective agreements)
generated as a result of licensing and otherwise enforcing the respective patents or patent portfolios.
The Company’s operating subsidiaries may retain the services
of law firms that specialize in patent licensing and enforcement and patent law in connection with their licensing and enforcement activities. These
law firms may be retained on a contingent fee basis whereby such law firms are paid a percentage of any negotiated fees, settlements or
judgments awarded.
The Company’s operating subsidiaries may engage with funding
sources that provide financing for patent licensing and enforcement. These litigation finance firms may be engaged on a non-recourse
basis whereby such litigation finance firms are paid a percentage of any negotiated fees, settlements or judgments awarded in exchange
for providing funding for legal fees and out of pocket expenses incurred as a result of the licensing and enforcement activities.
The economic terms of the inventor agreements, operating agreements,
contingent legal fee arrangements and litigation financing agreements associated with the patent portfolios owned or controlled by the
Company’s operating subsidiaries, if any, including royalty rates, contingent fee rates and other terms, vary across the patent
portfolios owned or controlled by such operating subsidiaries. Inventor/former owner royalties, payments to non-controlling interests,
contingent legal fees expenses and litigation finance expenses fluctuate period to period, based on the amount of revenues recognized
each period, the terms and conditions of revenue agreements executed each period and the mix of specific patent portfolios with varying
economic terms and obligations generating revenues each period. Inventor/former owner royalties, contingent legal fees expenses and litigation
finance expenses will continue to fluctuate and may continue to vary significantly period to period, based primarily on these factors.
Revenue Recognition
The Company recognizes revenue in accordance with ASC Topic 606,
“Revenue from Contracts with Customers”. Revenue is recognized when control of the promised goods or services is transferred
to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or
services. Under Topic 606, revenue is recognized when there is a contract which has commercial substance which is approved by both parties
and identifies the rights of the parties and the payment terms.
Patent Licensing Fees
Revenue is recognized upon transfer of control of promised bundled intellectual
property rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive
in exchange for those intellectual property rights. Revenue contracts that provide promises to grant “the right” to use intellectual
property rights as they exist at the point in time at which the intellectual property rights are granted, are accounted for as performance
obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are
satisfied and all other revenue recognition criteria have been met.
For the periods presented, revenue contracts executed by the Company primarily
provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain intellectual
property rights for patented technologies owned or controlled by the Company’s operating subsidiaries. Intellectual property rights
granted included the following, as applicable: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or
sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and
(iv) the dismissal of any pending litigation. The intellectual property rights granted were perpetual in nature, extending until
the legal expiration date of the related patents. The individual intellectual property rights are not accounted for as separate performance
obligations, as (a) the nature of the promise, within the context of the contract, is to transfer combined items to which the promised
intellectual property rights are inputs and (b) the Company’s promise to transfer each individual intellectual property right described
above to the customer is not separately identifiable from other promises to transfer intellectual property rights in the contract.
Since the promised intellectual property rights are not individually distinct,
the Company combined each individual IP right in the contract into a bundle of IP rights that is distinct,and accounted for all of the
intellectual property rights promised in the contract as a single performance obligation. The intellectual property rights granted were
“functional IP rights” that have significant standalone functionality. The Company’s subsequent activities do not substantively
change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. The Company’s
subsidiaries have no further obligation with respect to the grant of intellectual property rights, including no express or implied obligation
to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant (i.e. transfer of control)
of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally
obtain control of the intellectual property rights upon execution of the contract. As such, the earnings process is complete and revenue
is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been
met. Revenue contracts generally provide for payment of contractual amounts within 30-90 days of execution of the contract. Contractual
payments made by licensees are generally non-refundable. We do not have any significant payment terms, as payment is received shortly
after goods are delivered or services are provided, therefore there is no significant financing component or consideration payable to
the customer in these transactions.
Licensed Sales
The balance of the Company’s revenue in 2019, from licensed sales,
was not significant but included sales-based revenue contracts pursuant to purchase orders. There was no sales-based revenue in 2020.
There is only one distinct performance obligation in each purchase order, transfer of the promised good to the customer, and the customer
can benefit from the good together with other resources readily available to the customer. For licensed sales, the transaction price is
allocated to the performance obligation on a relative standalone selling price basis per the purchase order, and the Company includes
in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that
a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved. Estimates are generally based on historical levels of activity, if available. Notwithstanding,
revenue is recognized for a licensed sale when the performance obligation has been satisfied – transfer of the good
to the customer. The purchase order generally provides for payment of contractual amounts within 30 days of transfer of the goods to the
customer, therefore there is no significant financing component or consideration payable to the customer in these transactions.
Stock-based compensation
The Company recognizes stock-based compensation pursuant to ASC 718,
“Compensation — Stock Compensation,” which prescribes accounting and reporting standards for all stock-based payment
transactions in which employee services, and, since January 1, 2019, non-employee services, are acquired. Transactions include incurring
liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock
appreciation rights. Stock-based payments to employees and non-employees, including grants of employee stock options, are recognized as
compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an
employee or non-employee is required to provide services in exchange for the award, known as the requisite service period (usually the
vesting period).
Recent Accounting Pronouncements
Management does not believe that there are any recently issued, but
not effective, accounting standards which, if currently adopted, would have a material effect on the Company’s financial statements.
Going Concern
As shown in the accompanying financial statements, the Company has
an accumulated deficit of approximately $27,131,000 and negative working capital of approximately $10,781,000 as of June 30, 2021. Because
of the Company’s continuing losses, its working capital deficiency, the uncertainty of future revenue, the Company’s obligations
to Intellectual Ventures, Intelligent Partners, QPRC Finance LLC (“QFL”), the Company’s low stock price and the absence
of an active trading market in its common stock, the ability of the Company to raise funds in the equity market or from lenders is severely
impaired. These conditions, together with the effects of the COVID-19 pandemic and the steps taken by the states to slow the spread of
the virus and its effect on its business raise substantial doubt as to the Company’s ability to continue as a going concern. Although
the Company may seek to raise funds and to obtain third party funding for litigation to enforce its intellectual property rights, the
availability of such funds, particularly in view of the COVID-19 pandemic, is uncertain. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
NOTE 3 – SHORT-TERM DEBT AND LONG-TERM LIABILITIES
The following table shows the Company’s short-term and long-term
debt at June 30, 2021 and December 31, 2020.
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2021
|
|
|
2020
|
|
Short-term debt:
|
|
|
|
|
|
|
Loans payable
|
|
$
|
138,000
|
|
|
$
|
147,000
|
|
Funding liability
|
|
|
2,950,000
|
|
|
|
-
|
|
Loan payable – related party
|
|
|
2,805,000
|
|
|
|
4,672,810
|
|
Purchase price of patents – current portion
|
|
|
1,385,049
|
|
|
|
1,500,000
|
|
Unamortized discount
|
|
|
(12,612
|
)
|
|
|
-
|
|
Net short-term debt
|
|
$
|
7,265,437
|
|
|
$
|
6,319,810
|
|
|
|
|
|
|
|
|
|
|
Long-term liabilities:
|
|
|
|
|
|
|
|
|
Loans payable - SBA
|
|
|
|
|
|
|
|
|
Gross
|
|
$
|
150,000
|
|
|
$
|
170,832
|
|
Accrued Interest
|
|
|
6,350
|
|
|
|
3,560
|
|
Net loans payable - SBA
|
|
|
156,350
|
|
|
|
174,392
|
|
Purchase price of patents
|
|
|
|
|
|
|
|
|
Gross
|
|
|
790,000
|
|
|
|
790,000
|
|
Unamortized discount
|
|
|
(70,324
|
)
|
|
|
(131,793
|
)
|
Net purchase price of patents – long-term
|
|
$
|
719,676
|
|
|
$
|
658,207
|
|
The loans payable represents demand loans made by former officers and
directors, who are unrelated third parties at June 30, 2021, and December 31, 2020, in the amount of $138,000 and 147,000, respectively.
The loans are payable on demand plus accrued interest at 10% per annum. These third parties are also minority stockholders, but their
stockholdings are not significant.
The funding liability at June 30, 2021 represents the principal amount
of the Company’s obligations to QFL, a non-affiliated party, pursuant to a purchase agreement (“Purchase Agreement”)
dated February 22, 2021 between the Company and QFL, as described below. The obligation to QFL is classified as a current liability as
of June 30, 2021.
On February 22, 2021, the Company entered into a series of agreements,
all dated February 19, 2021,with QFL, including the “Purchase Agreement, a security agreement (the “Security Agreement”),
a subsidiary security agreement (the “Subsidiary Security Agreement”), a subsidiary guaranty (the “Subsidiary Guarantee”),
a warrant issue agreement (the “Warrant Issue Agreement”), a registration rights agreement (the “Registration Rights
Agreement”) and a board observation rights agreement (the “Board Observation Rights Agreement” together with the Security
Agreement, the Subsidiary Guaranty, the Subsidiary Security Agreement, Warrant Issuance Agreement, Registration Rights Agreement and the
Purchase Agreement, the “Investment Documents”) pursuant to which, at the closing held contemporaneously with the execution
of the agreements:
|
(i)
|
Pursuant to the Purchase Agreement, QFL agreed to make available to the Company a financing facility of: (a) up to $25,000,000 for the acquisition of mutually agreed patent rights that the Company intends to monetize; (b) up to $2,000,000 for operating expenses; and (iii) $1,750,000 to fund the cash payment portion of the restructure of the Company’s obligations to Intelligent Partners. In return the Company transferred to QFL a right to receive a portion of net proceeds generated from the monetization of those patents.
|
|
(ii)
|
The Company used $1,750,000 of proceeds from the QFL financing as the cash payment portion of the restructure of the Company’s obligations to Intelligent Partners pursuant to the Restructure Agreement executed contemporaneously with the closing of the Investment Documents. The payment was made directly from QFL to Intelligent Partners.
|
|
(iii)
|
Pursuant to the Security Agreement, the Company’s obligations under the Purchase Agreement with QFL are secured by: (a) the proceeds (as defined in the Purchase Agreement); (b) the patents (as defined in the Purchase Agreement; (c) all general intangibles now or hereafter arising from or related to the foregoing (a) and (b); and (d) proceeds (including, without limitation, cash proceeds and insurance proceeds) and products of the foregoing (a)-(c).
|
|
(iv)
|
Pursuant to the Subsidiary Guaranty, eight of the Company’s subsidiaries –QLC, NetTech, Mariner, Semcon, IC, CXT, M-Red, and AMI, collectively, the “Subsidiary Guarantors”) guaranteed the Company’s obligations to QFL under the Purchase Agreement.
|
|
(v)
|
Pursuant to the Subsidiary Security Agreement, the Subsidiary Guarantors granted QFL a security interest in the proceeds from the future monetization of their respective patent portfolios.
|
|
(vi)
|
Pursuant to the Warrant Issue Agreement, the Company granted QFL ten-year warrants to purchase a total of up to 96,246,246 shares of the Company’s common stock, at an exercise price of $0.0054 per share which may be exercised from the date of exercise through February 18, 2031 on a cash or cashless basis. Exercisability of the warrant is limited if, upon exercise, the holder or any of holder’s affiliates would beneficially own more than 4.99% (the “Maximum Percentage”) of the Company’s common stock, except that by written notice to the Company, the holder may change the Maximum Percentage to any other percentage not in excess of 9.99% provided any such change will not be effective until the 61st day following notice to the Company. The warrant also contains certain minimum ownership percentage antidilution rights pursuant to which the aggregate number of shares of common stock purchasable upon the initial exercise of the warrant shall not be less than 10% of the aggregate number of outstanding shares of capital stock of the Company (determined on a fully diluted basis). A portion of any gain from sale of the shares, net of taxes and costs of exercise, realized prior to the completion of all monetization activities shall be credited against the total return due to QFL pursuant to the Purchase Agreement. See Notes 4 and 5 for information on the warrant issuance and associated liability.
|
|
(vii)
|
The Company agreed to take all commercially reasonable steps necessary to regain compliance with the OTCQB eligibility standards as soon as practicable, but in no event later than 12 months from the closing date. The Company regained such compliance on May 7, 2021, at which time the common stock recommenced trading on the OTCQB.
|
|
(viii)
|
The Company granted QFL certain registration rights with respect to the 96,246,246 shares of common stock issuable upon exercise of the warrant. See Note 5 for information on the warrant issuance.
|
|
(ix)
|
Pursuant to the Board Observation Rights Agreement, until the later of the date on which QFL or its affiliates (i) have received the entirety of their Investment Return (as defined in Purchase Agreement), and (ii) no longer hold any Securities (the “Observation Period”), the Company granted QFL the right, exercisable at any time during the Observation Period, to appoint a representative to attend meetings (including, without limitation, telephonic or other electronic meetings) of the Board or any committee thereof, including executive sessions, in an observer capacity.
|
On February 26, 2021, the Company entered into an agreement with Peter
K. Trzyna (“PKT”) pursuant to which PKT assigned to the Company all right, title, and interest in a portfolio of eight United
States patents (the “Peregrin Portfolio”). Under the agreement, the Company paid PKT $350,000 at closing and agreed that upon
the realization of gross proceeds, if any, the Company shall make a second installment payment or payments in the aggregate amount of
$93,900 representing reimbursement to PKT, as the prosecuting attorney, for legal fees associated with prosecution of the portfolio, such
reimbursement shall be due and payable to PKT from time to time as gross proceeds are realized, and paid to PKT along with and in proportion
to reimbursement to other third parties of costs incurred in realizing gross proceeds from the Peregrin Portfolio. Thereafter, PKT is
entitled to a percentage of gross proceeds realized, if any, from the Peregrin Portfolio. The Company requested and received a capital
advance from QFL in the amount of $350,000 pursuant to the Purchase Agreement, which was used to make payment to PKT.
On May 20, 2021, Taasera Licensing LLC, a wholly owned subsidiary,
entered into an agreement with Taasera, Inc. to acquire all right, title, and interest in a portfolio of seven United States patents (the
“Taasera Portfolio”) for $250,000, payable at the closing to be held within 30 days of execution. The Company requested and
received a capital advance from QFL in the amount of $250,000 pursuant to the Purchase Agreement, which was used to make payment to Taasera,
Inc.
The Company requested and received an operating capital advance in
the amount of $600,000 from QFL pursuant to the Purchase Agreement during the period ended June 30, 2021.
The loan payable – related party at June 30, 2021 represents
the current amount of a non-interest bearing total monetization proceeds obligation (the “TMPO”) to Intelligent Partners,
LLC (“Intelligent Partners”) of $2,805,000, pursuant to a restructure agreement (“Restructure Agreement”) dated
February 22, 2021 whereby the Company and Intelligent Partners, extinguished the Company’s 10% note to Intelligent Partners as transferee
of the notes issued to United Wireless Holdings, Inc. (“United Wireless”), in the amount of $4,672,810 pursuant to securities
purchase agreement dated October 22, 2015 between the Company and United Wireless, as more fully described in the Company’s annual
report on Form 10-K for the year ended December 31, 2020. The notes became due by their terms on September 30, 2020, and the Company did
not make any payment on account of principal and interest on the notes. Subsequent to September 30, 2020, the Company engaged in negotiations
with Intelligent Partners in parallel with the Company’s negotiations with QFL, with a view to restructuring the Company’s
obligations under the United Wireless agreements, including the notes, so that the Company no longer had any obligations under the notes
or the SPA. These negotiations resulted in the Restructure Agreement, described below, which provided for the payment to Intelligent Partners
of $1,750,000 from the proceeds from the Company’s agreements with QFL. As part of the restructure of the Company’s agreements
with Intelligent Partners, the Company amended the existing monetization proceeds agreements (“MPAs”) and granted Intelligent
Partners certain rights in the monetization proceeds from any new intellectual property the Company acquires, as describe below. Under
these MPAs, Intelligent Partners participates in the monetization proceeds the Company receives with respect to new patents after QFL
has received its negotiated rate of return.
On or prior to the date of the Restructure Agreement, Intelligent Partners
transferred to Fitton and Carper $250,000 of the notes (the “Transferred Note”), thereby reducing the principal amount of
the notes held by Intelligent Partners to $4,422,810.
On February 22, 2021, the Company and Intelligent Partners agreed to
extinguish the notes and Transferred Note, and terminate or amend and restate the SPA and Transaction Documents, pursuant to a series
of agreements including: a Restructure Agreement (the “Restructure Agreement”), a Stock Purchase Agreement (the “Stock
Purchase Agreement”), an Option Grant (the “Option Grant”), an Amended and Restated Pledge Agreement (the “Pledge
Agreement”), an Amended and Restated Registration Rights Agreement (the “Registration Rights Agreement”), a Board Observation
Agreement (the “Board Observation Agreement”), a MPA-NA Security Interest Agreement (the “MPA-NA Security Interest Agreement”),
an Amended and Restated Patent Proceeds Security Agreement (the “Patent Proceeds Security Agreement”, an Amended and Restated
MPA-CP (the “MPA-CP”), an Amended and Restated MPA-CXT (the “MPA-CXT”), a MPA-MR (the “MPA-MR”), a
MPA-AMI (the “MPA-AMI,” and together with the MPA-CP, MPA-CXT and MPA-MR, each a Restructure MPA and together the Restructure
MPAs) and a MPA-NA (the “MPA-NA”).
|
(i)
|
Pursuant to the Restructure Agreement, the Company paid Intelligent Partners $1,750,000 at closing, which the Company received from QFL and which QFL paid directly to Intelligent Partners, and recognized the TMPO, which shall, from and after the Restructure Date, be reduced on a dollar for dollar basis by (a) payments to Intelligent Partners pursuant to the restructure agreement, the Restructure MPAs and the MPA-NA and (b) any election by the Intelligent Partners to pay the Exercise Price of the Restructure Option, in whole or part, by means of a reduction in the then outstanding TMPO. The TMPO has been classified as a current liability as of June 30, 2021.
|
|
(ii)
|
Pursuant to the Stock Purchase Agreement, the Company issued to Fitton and Carper, as holders of the Transferred Note, a total of 46,296,296 shares of common stock at a purchase price of $0.0054 per share, which purchase price was paid by the conversion and in full satisfaction of the Transferred Note (the “Conversion Shares”). For purposes of extinguishment, the issuance of the Conversion Shares in full satisfaction of the Transferred Note balance of $250,000 is included in the reacquisition price of the debt. The Company recognized a loss on debt conversion of $305,556 which is the difference between the agreed conversion price and the fair value of the Conversion Shares at the date of conversion. See Note 5 for information on the share issue.
|
|
(iii)
|
Pursuant to the Option Grant, we granted Intelligent Partners an option to purchase a total of 50,000,000 shares of common stock, with an exercise price of $0.0054 per share which vests immediately and may be exercised through September 30, 2025. The Company valued the option at approximately $598,000 using the Black-Scholes pricing model. The proceeds were allocated to the repurchase price of the debt extinguishment based on its fair value. See Note 5 for information on the option grant.
|
|
(iv)
|
Pursuant to the restructured monetization proceeds agreement, Intelligent Partners has a right to receive 60% of the net monetization proceeds from the patents currently owned by the Subsidiary Guarantors. The agreement has no termination provisions, so Intelligent Partners will be entitled to its percentage interest as long as revenue is generated from the intellectual property covered by the agreement.
|
|
(v)
|
Pursuant to the MPA-NA, until the TMPO has been paid in full, Intelligent Partners is entitled to receive 10% of the net proceeds realized from new assets acquired by the Company. If, in any calendar quarter, net proceeds realized exceed $1,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 30% on the portion of net proceeds in excess of $1,000,000 but less than $3,000,000. If in the same calendar quarter, net proceeds exceed $3,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 50% on the portion of net proceeds in excess of $3,000,000. After satisfaction of the TMPO, the MPA-NA and Intelligent Partners’ interest in new asset proceeds shall terminate.
|
|
(vi)
|
The Company granted Intelligent Partners, Andrew Fitton and Michael Carper certain registration rights with respect to (i) the 50,000,000 shares currently owned by Fitton and Carper; (ii) the 46,296,296 Conversion Shares issued to Fitton and Carper, and (iii) the 50,000,000 shares of common stock issuable upon exercise of the option. See Note 5
|
|
(vii)
|
Pursuant to the Subsidiary Security Agreement, the Company’s obligations under its agreements with Intelligent Partners, including its obligations under the Restructure Agreement and the Restructure MPAs are secured by a security interest in the net proceeds realized from the future monetization of the patents currently owned by the eight subsidiaries named above.
|
|
(viii)
|
Pursuant to the MPA-NA-Security Interest Agreement, our obligations under the MPA-NA are secured by a security interest in net proceeds realized from the future monetization of new patents acquired until the TMPO is satisfied, provided Intelligent Partners’ secured interest shall be limited to its entitlement in Net Proceeds under the MPA-NA. After satisfaction of the TMPO the security interest in proceeds from new assets shall terminate.
|
|
(ix)
|
Pursuant to the Board Observation Rights Agreement, until the Total Monetization Proceeds Obligation has been satisfied (the “Observation Period”), we granted Intelligent Partners the option and right, exercisable at any time during the Observation Period, to appoint a representative to attend meetings of the Board or any committee thereof, including executive sessions, in an observer capacity. Intelligent Partners has no right to appoint a director to the board.
|
Events of Default include (i) a Change of Control of the Company (ii)
any uncured default on payment due to Intelligent Partners in an amount totaling in excess of $275,000, which is not the subject of a
Dispute or other formal dispute resolution proceeding initiated in good faith pursuant to this Agreement or other Restructure Documents
(iii) the filing of a voluntary petition for relief under the United States Bankruptcy Code by Company or any of its material subsidiaries,
(iv) the filing of an involuntary petition for relief under the United States Bankruptcy Code against the Company, which is not stayed
or dismissed within sixty (60) days of such filing, except for an involuntary petition for relief filed solely by Intelligent Partners,
or any Affiliate or member of Intelligent Partners, or (v) acceleration of an obligation in excess of $1 million dollars to another provider
of financing following a final determination by arbitration or other judicial proceeding that such obligation is due and owing.
The Company recognized a loss on extinguishment of the note of $730,378
reflected as follows:
|
|
|
|
Carrying amount as of the restructure date
|
|
$
|
4,672,810
|
|
Less unamortized debt discount and issuance costs
|
|
|
-
|
|
Net carrying amount
|
|
|
4,672,810
|
|
Reacquisition Price
|
|
|
|
|
Cash payment via QFL
|
|
|
(1,750,000
|
)
|
Conversion of transferred note
|
|
|
(250,000
|
)
|
Fair value of option grant
|
|
|
(598,188
|
)
|
TMPO undiscounted future cash flows
|
|
|
(2,805,000
|
)
|
Loss on debt extinguishment
|
|
$
|
(730,378
|
)
|
Because of its ownership percentage, Intelligent Partners is treated
as a related party.
The purchase price of patents – current portion at June 30, 2021
represents the current portion of minimum payments due under the agreements between:
|
●
|
CXT and Intellectual Ventures Assets 34, LLC and Intellectual Ventures 37, LLC (“IV 34/37”) pursuant to which at closing CXT acquired by assignment all right, title, and interest in a portfolio of thirteen United States patents (the “CXT Portfolio”). Under the agreement, CXT will distribute 50% of net recoveries, as defined, to IV 34/37. CXT advanced $25,000 to IV 34/37 at closing, and agreed, pursuant to an amendment dated January 26, 2018, that in the event that, on December 31, 2018, December 31, 2019 and December 31, 2020, cumulative distributions to IV 34/37 total less than $100,000, $375,000 and $975,000, respectively, CXT shall pay the difference necessary to achieve the applicable minimum payment amount within ten days after the applicable date; with any advances being credited toward future distributions to IV 34/36. As of June 30, 2021, cumulative distributions totaling $375,000 had been made and CXT did not pay the $600,000 difference to IV 34/37 within ten days. As a result, the remaining $600,000 of the minimum future cumulative distributions due were presented as short-term debt based on payment due date. Non-payment which is not cured within 30 days after written notice from IV 34/37 would constitute an Acceleration Event under the agreement, following which, in addition to any other remedies available under the agreement, all outstanding minimum cumulative distributions would become due and payable within thirty days. As of the date of filing, no such written notice of non-payment has been given by IV 34/37. No affiliate of CXT has guaranteed the minimum payments. CXT’s obligations under the agreement are secured by a security interest in the proceeds (from litigation or otherwise) from the CXT Portfolio.
|
|
●
|
M-RED and Intellectual Ventures Assets 113 LLC and Intellectual Ventures Assets 108 LLC (“IV 113/108”) pursuant to which at closing M-RED paid IV 113/108 $75,000 and IV 113/108 transferred to M-RED all right, title and interest in a portfolio of sixty United States patents and eight foreign patents (the “M-RED Portfolio”). Under the agreement, M-RED will distribute 50% of net proceeds, as defined, to IV 113/108, as long as we generate revenue from the M-RED Portfolio. The agreement with IV 113/108 provides that if, on September 30, 2020, September 30, 2021 and September 30, 2022, cumulative distributions to IV 113/108 total less than $450,000, $975,000 and $1,575,000, respectively, M-RED shall pay the difference between such cumulative amounts and the amount paid to IV 113/108 within ten days after the applicable date; with any advances being credited toward future distributions to IV 113/108. On September 30, 2020 cumulative distributions to IV 113/108 totaled less than $450,000 and M-RED did not pay the difference to IV 113/108 within ten days. During the six months ended June 30, 2021, the Company made a payment in the amount of $114,951. Non-payment which is not cured within 30 days after written notice from IV 113/108 would constitute an Acceleration Event under the agreement, following which, in addition to any other remedies available under the agreement, all outstanding minimum cumulative distributions would become due and payable within thirty days. As of the date of filing, no such written notice of non-payment has been given by IV 113/108. As of June 30, 2021, approximately $785,000 and $600,000 of the minimum future cumulative distributions were presented as short-term and long-term debt, respectively, based on payment due dates. No affiliate of M-RED has guaranteed the minimum payments. M-RED’s obligations under the agreement with IV 113/108 are secured by a security interest in the proceeds (from litigation or otherwise) from the M-RED Portfolio.
|
Long term liabilities
The loans payable-SBA at June 30, 2021 represents:
|
●
|
An unsecured loan from JPMorgan Chase Bank, N.A. in the aggregate amount of $20,832, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, which was enacted March 27, 2020. The loan, which was taken down on April 23, 2020, matures on April 23, 2022 and bears interest at a rate of 0.98% per annum, with interest payable monthly commencing on November 23, 2020. The loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Funds from the loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred before February 15, 2020. The Company has used the entire loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. As of June 30, 2021 the loan has been forgiven and the Company recorded a gain on loan forgiveness of $20,832.
|
|
●
|
A secured Economic Injury Disaster Loan from the U.S. Small Business Association (“SBA”) in the aggregate amount of $150,000, pursuant to Section 7(b) of the Small Business Act as part of the COVID-19 relief effort. The Company’s obligations on the loan are set forth in the Company’s note dated May 14, 2020 which matures on May 14, 2050 and bears interest at a rate of 3.75% per annum, payable monthly commencing on May 14, 2022. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Funds from the Loan may be used solely as working capital to alleviate economic injury caused by disaster occurring in the month of January 31, 2020 and continuing thereafter and to pay Uniform Commercial Code (UCC) lien filing fees and a third-party UCC handling charge of $100 which were deducted from the loan amount stated above. In addition to the loan, as part of the COVID-19 relief effort, the Company obtained an Emergency EIDL Grant from the SBA in the amount of $1,000. The Company is not required to repay the grant.
|
The purchase price of patents at June 30, 2021 represents:
The non-current portion of minimum payments due under the agreement
between M-RED and IV 113/108 described above.
The non-current portion of our obligations under the unsecured non-recourse
funding agreement with a third-party funder entered into in May 2020 whereby the third-party agreed to provide acquisition funding in
the amount of $95,000 for the Company’s acquisition of the audio messaging portfolio. Under the funding agreement, the third party
funder is entitled to a priority return of funds advanced from net proceeds, as defined, recovered until the funder has received $190,000.
The Company has no other obligation to the third party and has no liability to the funder in the event that the Company does not generate
net proceeds. Pursuant to ASC 470, the company recorded this monetization obligation as debt and the difference between the purchase price
and total obligation as a discount to the debt and fully expensed to interest during the period.
The balance of the purchase price of the patents
is reflected as follows:
|
|
June 30,
2021
|
|
|
December 31, 2020
|
|
Current Liabilities:
|
|
|
|
|
|
|
Purchase price of patents, current portion
|
|
|
1,385,049
|
|
|
$
|
1,500,000
|
|
Unamortized discount
|
|
|
(12,612
|
)
|
|
|
-
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
|
Purchase price of patents, long term
|
|
|
790,000
|
|
|
$
|
790,000
|
|
Unamortized discount
|
|
|
(70,325
|
)
|
|
|
(131,793
|
)
|
Total current and non-current
|
|
|
2,092,112
|
|
|
|
2,158,207
|
|
Effective interest rate of Amortization over 2 years
|
|
|
9.4-14.5 %
|
|
|
|
9.4-14.5 %
|
|
Because the non-current minimum payment obligations
are due over a period of two years, the Company imputed interest of 10% per annum and the interest will be accreted up to the maturity
date.
NOTE 4 – WARRANT LIABILITY
The Company issued warrants to purchase 96,246,246 shares of common
stock to QFL (see Note 3) in connection with its funding agreement. Because if on the initial exercise date the aggregate number of warrant
shares purchasable upon exercise of the warrant would yield less than the an amount equal to 10% of the aggregate number of outstanding
shares of capital stock of the Company (determined on a fully diluted basis), then the number of warrant shares shall be increased to
an amount equal to 10% of the aggregate number of outstanding shares of capital stock of the Company (determined on a fully diluted basis),
the number of shares underlying the warrants is not fixed until the date of the initial exercise. As such, the warrant issued to QFL requires
classification as a liability pursuant to ASC Topic 480, Distinguishing Liabilities from Equity and is valued at its fair value as of
the grant date and re-measured at the balance sheet date.
As of June 30, 2021, and February 22, 2021, the date of issuance of
the warrant, the aggregate fair value of the outstanding warrant liability was approximately $1,539,940 and $1,154,905, respectively.
The Company estimated the fair value of the warrant liability using
the Black-Scholes option pricing model using the following key assumptions as of June 30, 2021 and as of the grant date:
|
|
As of
|
|
|
|
June 30,
|
|
|
February 22,
|
|
|
|
2021
|
|
|
2021
|
|
Volatility
|
|
|
401
|
%
|
|
|
252
|
%
|
Exercise price
|
|
|
0.0054
|
|
|
|
0.0054
|
|
Risk-free interest rate
|
|
|
1.37
|
%
|
|
|
1.37
|
%
|
Expected dividends
|
|
|
-
|
|
|
|
-
|
%
|
Expected term
|
|
|
9.65
|
|
|
|
10
|
|
The following schedule summarizes the valuation
of financial instruments at fair value in the balance sheets as of June 30, 2021 and the grant date:
|
|
Fair Value Measurements as of
|
|
|
|
June 30, 2021
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Assets
|
|
|
|
|
|
|
|
|
|
None
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total assets
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Option derivative liability
|
|
|
-
|
|
|
|
-
|
|
|
|
1,539,940
|
|
Total liabilities
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,539,940
|
|
The following table sets forth a reconciliation of changes in the fair
value of derivative liabilities classified as Level 3 in the fair value hierarchy:
|
|
Significant Unobservable
Inputs
(Level 3)
as of
June 30,
2021
|
|
Fair value at grant date
|
|
$
|
1,154,905
|
|
Change in fair value
|
|
|
385,035
|
|
Ending balance
|
|
$
|
1,539,940
|
|
See Notes 3 and 5 for information on the warrant issuance.
NOTE 5 – STOCKHOLDERS’ EQUITY
Amendment to the 2017 Equity Incentive Plan
On February 19, 2021 the board of directors amended the 2017 Equity
Incentive Plan (the “Plan”) increasing the shares the Company can issue under the Plan to 500,000,000 shares of common stock
pursuant to non-qualified stock options, restricted stock grants and other equity-based incentives, the amendment to the Plan and the
grants of awards pursuant to the Plan, to be effective upon the closing of the agreements with QFL.
Issuance of Common Stock and Options
Issuances to Intelligent Partners
On February 22, 2021, pursuant to the Restructure Agreement, Intelligent
Partners and its controlling members agreed to extinguish the notes and Transferred Note, and terminate or amend and restate the SPA and
Transaction Documents and the Company: (i) issued to Fitton and Carper, as holders of the Transferred Note, pursuant to the Stock Purchase
Agreement a total of 46,296,296 shares of the Company’s common stock at a purchase price of $0.0054 per share, which purchase price
was paid by the conversion and in full satisfaction of the Company’s obligation under the Transferred Note and included in the calculation
of the repurchase price of the debt; and (ii) granted Intelligent Partners, pursuant to the Option Grant, an option to purchase a total
of 50,000,000 shares of common stock, with an exercise price of $0.0054 per share which vested immediately and may be exercised through
September 30, 2025. The Company valued the purchase option at approximately $598,000 using the Black-Scholes pricing model. Variables
used in the valuation include (1) discount rate of 1.37%; (2) option life of 5 years; (3) computed volatility of 252% and (4) zero expected
dividends. The fair market value of the options was included in the loss on extinguishment calculation (see Note 3). The Company granted
Intelligent Partners, Andrew Fitton and Michael Carper certain registration rights with respect to (i) the 50,000,000 shares currently
owned by Fitton and Carper; (ii) the 46,296,296 Conversion Shares issued to Fitton and Carper, and (iii) the 50,000,000 shares of common
stock issuable upon exercise of the option. Commencing six months from the closing date, if the shares owned by Fitton, Carper and Intelligent
Partners cannot be sold pursuant to a registration statement and cannot be sold pursuant to Rule 144 without the Company being in compliance
with the current public information requirements of Rule 144, if the Company is not in compliance with the current public information
requirements, the Company is required to pay damages to Intelligent Partners.
Consulting Agreements
On February 22, 2021, the Company entered into advisory service agreement
with three consultants – William Gates, Crystal Nicolson and Jeff Toler pursuant to which they will provide services to the Company
in connection with the development of the Company’s business. The agreements have a term of ten years and may be terminated by the
Company for cause or upon the death or disability of the consultants.
Pursuant to the agreements with Mr. Gates and Ms. Nicolson, the compensation
payable to each of them consists of a restricted stock grant of 10,000,000 shares of Common Stock which immediately vests in full and
a ten-year option to purchase a total of 30,000,000 shares of Common Stock, which become exercisable cumulatively as follows:
|
a.
|
10,000,000 shares at an exercise price of $0.01 per share becoming exercisable upon the commencement of trading of the Common Stock on the OTCQB. The Company regained such compliance on May 7, 2021, at which time the common stock recommenced trading on the OTCQB.
|
|
b.
|
10,000,000 shares at an exercise price of $0.03 per share, becoming exercisable on the first day on which the Company files with the SEC a Form 10-K or Form 10-Q which stockholders’ equity of at least $5,000,000, and
|
|
c.
|
10,000,000 shares at an exercise price of $0.05 per share becoming exercisable on the date on which the Common Stock is listed for trading on the Nasdaq Stock Market or the New York Stock Exchange.
|
The Company recorded professional fees in the amount of $240,000 as
a result the restricted stock grants to Mr. Gates and Ms. Nicolson. The Company determined the fair value of the options as of the grant
date to be approximately $720,000 using the Black-Scholes pricing model. Variables used in the valuation include (1) discount rate of
1.37%; (2) term of 10 years; (3) computed volatility of 252% and (4) zero expected dividends. The Company met the first performance condition
and accrued the option expense of approximately $240,000 over the period from the grant date to achievement of the performance condition.
The Company recognized option expense of approximately $120,000 and approximately $240,000 for the three and six months ended June 30,
2021, respectively.
Pursuant to the agreement with Mr. Toler, the compensation payable
to him consists of a restricted stock grant of 10,000,000 shares of Common Stock which immediately vests in full and a ten-year option
to purchase 30,000,000 shares of Common Stock, which becomes exercisable cumulatively as follows:
|
a.
|
10,000,000 shares at an exercise price of $0.01 per share upon the first anniversary of the agreement.
|
|
b.
|
10,000,000 shares at an exercise price of $0.03 per share upon the second anniversary of the agreement; and
|
|
c.
|
10,000,000 shares at an exercise price of $0.05 per share upon the third anniversary of the agreement.
|
The Company recorded professional fees in the amount of $120,000 as
a result the restricted stock grant to Mr. Toler. The Company determined the fair value of the options as of the grant date to be approximately
$360,000 using the Black-Scholes pricing model. Variables used in the valuation include (1) discount rate of 1.37%; (2) term of 10 years;
(3) computed volatility of 252% and (4) zero expected dividends. The Company recognized option expense of approximately $55,000 and approximately
$77,000 for the three and six months ended June 30, 2021, respectively.
Compensatory Arrangements of Certain Officers
On February 22, 2021, the board of directors:
|
(i)
|
Granted restricted stock grants for services rendered and vesting in full upon grant, to:
|
|
a.
|
Jon C. Scahill – 49,000,000 shares
|
|
b.
|
Timothy J. Scahill – 10,000,000 shares
|
|
c.
|
Dr. William R. Carroll - 10,000,000 shares
|
|
(ii)
|
Granted Jon Scahill a ten-year option (the “Option”) to purchase 60,000,000 shares of Common Stock which become exercisable cumulatively as follows:
|
|
a.
|
20,000,000 shares at an exercise price of $0.01 per share becoming exercisable upon the commencement of trading of the Common Stock on the OTCQB. The Company regained such compliance on May 7, 2021, at which time the common stock recommenced trading on the OTCQB.
|
|
b.
|
20,000,000 shares at an exercise price of $0.03 per share, becoming exercisable on the first day on which the Company files with the SEC a Form 10-K or Form 10-Q which stockholders” equity of at least $5,000,000, and
|
|
c.
|
20,000,000 shares at an exercise price of $0.05 per share becoming exercisable on the date on which the Common Stock is listed for trading on the Nasdaq Stock Market or the New York Stock Exchange
|
|
(iii)
|
Appointed Ryan T. Logue to the board of directors and granted Mr. Logue a restricted stock grant of 5,000,000 shares of common stock which vests upon his acceptance of his appointment as a director.
|
The Company recognized compensation expense of $888,000 in conjunction
with issuance of common stock to officers and directors. The Company determined the fair value of the options to be approximately $720,000
as of the grant date using the Black-Scholes pricing model. Variables used in the valuation include (1) discount rate of 1.37%; (2) term
of 10 years; (3) computed volatility of 252% and (4) zero expected dividends. The Company recognized option expense of approximately $120,000
and approximately $240,000 for the three and six months ended June 30, 2021.
A summary of the status of the Company’s stock options and changes
is set forth below:
|
|
Number of
Options (#)
|
|
|
Weighted
Average
Exercise
Price ($)
|
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
Balance - December 31, 2020
|
|
-
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
200,000,000
|
|
|
|
0.02
|
|
|
|
8.65
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Cancelled
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Balance – June 31, 2021
|
|
|
200,000,000
|
|
|
|
0.02
|
|
|
|
8.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at end of period
|
|
|
100,000,000
|
|
|
|
0.0077
|
|
|
|
6.95
|
|
The intrinsic value of the outstanding options as of June 30, 2021
is $830,000.
Issuance of Warrants
A summary of the status of the Company’s warrants and changes
is set forth below:
|
|
Number of
Warrants (#)
|
|
|
Weighted
Average
Exercise
Price ($)
|
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
Balance - December 31, 2020
|
|
-
|
|
|
-
|
|
|
-
|
|
Granted
|
|
|
96,246,246
|
|
|
|
0.0054
|
|
|
|
9.89
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Cancelled
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Balance – June 30, 2021
|
|
|
96,246,246
|
|
|
|
0.0054
|
|
|
|
9.64
|
|
The intrinsic value of the outstanding warrants as of June 30, 2021
is $1,020,210.
NOTE 6 – INTANGIBLE ASSETS
Intangible assets include patents purchased
and are recorded based at their acquisition cost. Intangible assets consisted of the following:
|
|
|
|
|
|
|
|
Weighted
average
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
amortization
period
|
|
|
|
2021
|
|
|
2020
|
|
|
(years)
|
|
Patents
|
|
$
|
6,290,000
|
|
|
$
|
5,690,000
|
|
|
|
4.45
|
|
Less: net monetization obligations
|
|
|
(509,811
|
)
|
|
|
(509,811
|
)
|
|
|
|
|
Imputed interest
|
|
|
(713,073
|
)
|
|
|
(713,073
|
)
|
|
|
|
|
Subtotal
|
|
|
5,067,116
|
|
|
|
4,467,116
|
|
|
|
|
|
Less: accumulated amortization
|
|
|
(3,142,305
|
)
|
|
|
(2,266,157
|
)
|
|
|
|
|
Net value of intangible assets
|
|
$
|
1,924,813
|
|
|
$
|
2,220,959
|
|
|
|
3.58
|
|
Intangible assets are comprised of patents
with estimated useful lives. The intangible assets at June 30, 2021 represent:
|
●
|
patents acquired in October 2015 for a purchase price of $3,000,000, the useful lives of the patents, at the date of purchase, was 6-10 years;
|
|
●
|
patents acquired in July 2017 pursuant to an obligation to distribute 50% of net revenues to IV 34/37, against which $25,000 was advanced at closing and provided that in the event that, on December 31, 2018, December 31, 2019 and December 31, 2020, cumulative distributions of 50% of net revenues to IV 34/37 total less than $100,000, $375,000 and $975,000, respectively, CXT shall pay the difference necessary to achieve the applicable minimum payment amount within ten days after the applicable date; with any advances being credited toward future distributions to IV 34/36; the useful lives of the patents, at the date of acquisition, was 5-6 years;
|
|
●
|
patents (which were fully depreciated at the date of acquisition) acquired in January 2018 pursuant to an agreement with to Intellectual Ventures Assets 62 LLC and Intellectual Ventures Assets 71 LLC “(IV 62/71”), pursuant to which CXT has an obligation to distribute 50% of net revenues to IV 62/71 against which CXT advanced $10,000 at closing;
|
|
●
|
patents acquired in January 2018 by PIS from Intellectual Ventures Assets 64 LLC (“IV 64”) pursuant to which PIS is to pay IV 64 (a) 70% of the first $1,500,000 of net revenue, (b) 30% of the next $1,500,000 of net revenue and (c) 50% of net revenue in excess of $3,000,000, against which PIS advanced $10,000 at closing; and
|
|
●
|
patents acquired in March 2019 by M-Red from Intellectual Ventures Assets 113 LLC and Intellectual Ventures 108 LLC (“IV 113/108”) pursuant to which M-Red is obligated to distribute 50% of net revenues to IV 113/108, against which $75,000 was advanced at closing and provided that in the event that, on September 30, 2020, September 30, 2021 and September 30, 2022, cumulative distributions of 50% of net revenues to IV 113/108 total less than $450,000, $975,000 and $1,575,000, respectively, M-Red shall pay the difference necessary to achieve the applicable minimum payment amount within ten days after the applicable date; with any advances being credited toward future distributions to IV 113/108; the useful lives of the patents, at the date of acquisition, was approximately nine years; and
|
|
●
|
patents (which were fully depreciated at the date of acquisition) acquired in May 2020 for a purchase price of $95,000 pursuant to an agreement with Texas Technology Ventures 2, LLP (“TTV”), pursuant to which of the Company retains the first $230,000 of net proceeds, as defined in the agreement, after which the company has an obligation to distribute 50% of net proceeds to TTV.
|
|
|
|
|
●
|
patents (which were fully amortized at the date of acquisition) acquired in February 2021 pursuant to an agreement with PKT for a purchase price of $350,000, pursuant to which $350,000 was paid at closing, and upon the realization of gross proceeds, as defined in the agreement, the Company shall make a subsequent or payments in the aggregate amount of $93,900, representing reimbursement to PKT, as the prosecuting attorney, for legal fees associated with prosecution of the portfolio, such reimbursement shall be due and payable to PKT from time to time as gross proceeds are realized, if any, and paid to PKT along with and in proportion to reimbursement to other third parties of costs incurred in realizing gross proceeds. Thereafter, PKT is entitled to a percentage of gross proceeds realized, if any.
|
|
|
|
|
●
|
patents (which were fully depreciated at the date of acquisition) acquired in May 2021 for a purchase price of $250,000.
|
The Company amortizes the costs of intangible
assets over their estimated useful lives on a straight-line basis. Costs incurred to acquire patents, including legal costs, are
also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included
as a selling, general and administrative expense in the accompanying consolidated statements of operations.
The Company assesses intangible assets for any impairment to the carrying
values. As of June 30, 2021, and December 31, 2020, management concluded that there was no impairment to the acquired assets.
Amortization expense for patents comprised $388,259 and $876,147 for the
three and six months ended June 30, 2021, respectively, and$233,256 and $371,512 for the three and six months ended June 30, 2020, respectively.
Future amortization of intangible assets is as follows:
Year ended December 31,
|
|
|
|
Remainder of 2021
|
|
$
|
273,199
|
|
2022
|
|
|
495,742
|
|
2023
|
|
|
323,071
|
|
2024
|
|
|
306,776
|
|
2025 and thereafter
|
|
|
526,025
|
|
Total
|
|
$
|
1,924,813
|
|
Pursuant to the securities purchase agreement
dated October 22, 2015 between the Company and United Wireless, more fully described in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2020, 15% of the net monetization proceeds from the patents acquired in October 2015 will be paid to Intelligent
Partners, as transferee of United Wireless. This monetization obligation was recognized as a discount to the loan and will be amortized
over the life of the loan using the effective interest method. In addition, the Company entered into a monetization agreement with United
Wireless pursuant to which the Company agreed to pay United Wireless 7.5% of the net monetization proceeds from the patents acquired by
CXT in July 2017. This obligation was recorded as an expense and is reflected in interest expense during the third quarter of 2017. See
Note 3 in connection with the extinguishment of the Company’s 10% notes issued to United Wireless and held by Intelligent Partners
as the transferee of United Wireless.
Because certain non-current minimum payment
obligations were due over a period of two years, the Company calculated imputed interest which will be accreted up to the maturity date
(see Note 3).
The Company granted Intellectual Ventures
a security interest in the patents assigned to the Company as security for the payment of the balance of the purchase price. The security
interest of Intellectual Ventures is senior to the security interest of United Wireless in the proceeds derived from such patents.
NOTE 7 – RELATED PARTY TRANSACTIONS
The Company has at various times entered into transactions with related
parties, including officers, directors and major stockholders, wherein these parties have provided services, advanced or loaned money,
or both, to the Company which was needed to support its daily operations. The Company discloses all related party transactions.
In prior periods, the Company incurred interest expense on the Company’s
10% notes issued to United Wireless pursuant to the securities purchase agreement dated October 22, 2015 more fully described in the Company’s
annual report on Form 10-K for the year ended December 31, 2020. The notes were extinguished in February 2021 and the Company did not
incur interest expense on the notes during the three and six months ended June 30, 2021. During the three and six months ended June 30,
2020 the Company paid the amounts due of approximately $116,500 and $233,000 in interest, respectively. See Notes 3 and 5 in connection
with the extinguishment of the Company’s 10% notes issued to United Wireless and held by Intelligent Partners as the transferee
of United Wireless.
See Note 8 with respect to the employment agreement with the Company’s
president and chief executive officer.
During the three and six months ended June 30, 2021 and 2020, the Company
contracted with an entity owned by the chief technology officer for the provision of information technology services to the Company. The
cost of such services was approximately $90 and $205 for the three and six months ended June 30, 2021, respectively, and approximately
$90 and $205 for the three and six months ended June 30, 2020, respectively.
During the three and six months ended June 30, 2021, the Company contracted
with a law firm more than 10 percent owned, but not controlled, by the father-in-law of the chief executive officer. The firm is engaged
on a contingent fee basis and serves as escrow agent in connection with monetization of the Company’s patents in matters where the
firm is serving as counsel to the Company. In connection with the engagement, the Company recorded patent service costs of $0 for the
three and six months ended June 30, 2021 and an outstanding liability of approximately $407,000 reported in “accounts payable and
accrued liabilities” in the consolidated balance sheets as of June 30, 2021 and December 31, 2020.
NOTE 8 – COMMITMENTS AND CONTINGENCIES
Employment Agreements
Pursuant to a restated employment agreement, dated November 30, 2014,
with the Company’s president and chief executive officer, the Company agreed to employ him as president and chief executive officer
for a term of three years, commencing January 1, 2014, and continuing on a year-to-year basis unless terminated by either party on not
less than 90 days’ notice prior to the expiration of the initial term or any one-year extension. The agreement provides for an initial
annual salary of $252,000, which may be increased, but not decreased, by the board or the compensation committee. In March 2016, the Company’s
board of directors increased the chief executive officer’s annual salary to $300,000, effective January 1, 2016. The chief executive
officer is entitled to a bonus if the Company meets or exceeds performance criteria established by the compensation committee. In August
2016, the Company’s board of directors approved annual bonus compensation equal to 30% of the amount by which the Company’s
consolidated income before income taxes exceeds $500,000, but, if the Company is subject to the limitation on deductibility of executive
compensation pursuant to Section 162(m) of the Internal Revenue Code, the bonus cannot exceed the amount which would be deductible pursuant
to Section 162(m). The chief executive officer is also eligible to participate in any executive incentive plans which the Company may
adopt.
Pension Benefits
Pursuant to the SEP IRA plan adopted by the Company in March 2020 the
Company deposited into a SEP IRA account of each of its participating employees a percentage of the employee’s compensation, subject
to statutory limitations on the amount of the contribution all as set forth in the IRS Form 5305-SEP. For the year ending December 31,
2021 the percentage is set at 19%. The Company’s president and chief executive officer is the only participant and for the six months
ended June 30, 2021 $29,000 was deposited into his SEP IRA account.
Patent Enforcement and Other Litigation
Certain of the Company’s operating subsidiaries are engaged in
litigation to enforce their patents and patent rights. In connection with these patent enforcement actions, it is possible that a
defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal
rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In
such event, a court may issue monetary sanctions against the Company or its operating subsidiaries or award attorney’s fees and/or
expenses to a defendant(s), which could be material, and if required to be paid by the Company or its operating subsidiaries, could materially
harm the Company’s operating results and financial position and could result in a default under the Company’s notes to Intelligent
Partners. Since the operating subsidiaries do not have any assets other than the patents, and the Company does not have any available
financial resources to pay any judgment which a defendant may obtain against a subsidiary, such a judgment may result in the bankruptcy
of the subsidiary and/or the loss of the patents, which are the subsidiaries’ only assets.
NOTE 9 – SUBSEQUENT EVENTS
On July 23, 2021, the Company paid $1,150,000 in full satisfaction
of the disputed and unpaid legal services performed by the Company’s former legal counsel for services relating to the monetization
of the Company’s intellectual property rights. A former minority partner of the firm is the father-in-law of the Company’s
chief executive officer.
On August 6, 2021 the Company acquired all of the issued and outstanding
equity interests of Soundstreak Texas, LLC from Soundstreak, LLC for the a purchase price consisting of 50% of the net proceeds resulting
from monetization of the Soundstreak Texas, LLC patent portfolio.